Innovating ADCs with Tubutecan Technology from Bench to Bedside: Highlighting Development of TUB-040, a NaPi2b-Targeting ADC

  • Detailing comprehensive preclinical evaluation of TUB-040 and work leading to translation into the clinic
  • Explaining TUB-040 ADC design innovation across payload, conjugation and target
  • Highlighting the clinical development strategy and potential therapeutic impact of TUB-040